AQST Aquestive Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AQST

Price (delayed)

$4.165

Market cap

$522.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.62

Enterprise value

$545.34M

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 18

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
AQST's equity is up by 44% year-on-year
Aquestive Therapeutics's quick ratio has increased by 27% QoQ but it has decreased by 14% YoY
AQST's net income is down by 27% year-on-year but it is up by 18% since the previous quarter
The debt has grown by 7% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://aquestive.com
Peers: OPK ORGO

Key stats

What are the main financial stats of AQST

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
3.35%
1 week
3.61%
1 month
-1.3%
1 year
22.14%
YTD
-35.53%
QTD
0.36%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$50.27M
Gross profit
$31.9M
Operating income
-$55.89M
Net income
-$68.91M
Gross margin
63.5%
Net margin
-137.1%
Aquestive Therapeutics's operating margin has decreased by 47% YoY but it has increased by 30% QoQ
The net margin has contracted by 37% YoY but it has grown by 27% from the previous quarter
The operating income has decreased by 36% YoY but it has increased by 21% from the previous quarter
AQST's net income is down by 27% year-on-year but it is up by 18% since the previous quarter

Price vs fundamentals

How does AQST's price correlate with its fundamentals

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
10.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.85
The EPS has grown by 21% since the previous quarter but it has declined by 5% year-on-year
AQST's equity is up by 44% year-on-year
AQST's P/S is 101% above its 5-year quarterly average of 4.9 but 17% below its last 4 quarters average of 11.8
Aquestive Therapeutics's revenue has increased by 13% from the previous quarter but it has decreased by 7% YoY

Efficiency

How efficient is Aquestive Therapeutics business performance
The return on sales has dropped by 51% year-on-year but it has grown by 31% since the previous quarter
The company's return on invested capital fell by 43% YoY but it rose by 21% QoQ
AQST's ROA is up by 24% since the previous quarter

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 19% lower than its total liabilities
The company's total assets rose by 38% YoY but it fell by 12% QoQ
The current ratio has increased by 31% since the previous quarter but it has declined by 16% year-on-year
AQST's debt to equity has dropped by 92% year-on-year
AQST's equity is up by 44% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.